Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhichan Granules (止颤颗粒) is a Traditional Chinese Medicine (TCM) formulation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine for the treatment of Parkinson's disease. The name "Zhichan" translates to "stopping tremors," reflecting its primary clinical focus on alleviating motor symptoms. It is typically used as an adjunctive therapy to standard dopaminergic treatments, such as levodopa, to improve motor function, reduce tremors, and potentially mitigate complications like levodopa-induced dyskinesia. Clinical research, including trials registered in the Chinese Clinical Trial Registry (ChiCTR), suggests that the formula may exert neuroprotective effects and modulate neurotransmitter balance, although its exact multi-component mechanism remains a subject of ongoing study.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhichan granules.